Clinical Trial Update: A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating SAGE-217 (zuranolone) in adults with Major Depressive Disorder has completed, with results posted on 2024-07-18. The sponsor is Biogen.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• SAGE-217 (zuranolone)

Snippet

Sponsor: Biogen | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2024-07-18